

Date: 8th November, 2023

To,

Listing Compliances, BSE Limited, P. J. Towers, Fort, Mumbai - 400001. Scrip Code: 539938; Scrip Id: MIL	Listing Compliances, CSE - India, 7, Lyons Range, Dalhousie Kolkata - 700001.
--	---

Subject: Outcome of Board Meeting and Compliances of Regulation 30, 33 and 42 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Dear Sir/Ma'am,

Pursuant to provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., November 08, 2023, inter alia, considered and approved Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended on September 30, 2023 along with Limited Review Report issued by M/s. V Goswami & Co, Statutory Auditors of the Company.

Further, please find enclosed "Standalone and Consolidated Unaudited Financial Results, Statement of Assets and Liabilities and Cash Flow Statement along with Limited Review Report" for the quarter ended on September 30, 2023 as **Annexure 1** and same is also available on the website of the Company viz. www.medicointercontinental.com

The Board Meeting of the Company commenced at 03:30 PM and concluded at 04:40 PM.

This is for your information and records.

Thanking You,

FOR MEDICO INTERCONTINENTAL LIMITED

Puneeta Sharma
Company Secretary & Compliance Officer
Membership No. A42989



V.GOSWAMI & CO.
CHARTERED ACCOUNTANTS

ICAI REG NO. :- 128769W
RBI UCN NO. :- 897783
C&AG REG NO. :- WR4659
GST :- 24AAFHV3075F1Z7

3, SF, Manek Appt, Nr. Jain Derasar, B/s. Tagor Park, Nehrunagar Circle, Ahmedabad - 380015.
M : +91 94287 33430, +91 97247 28711 | E-mail : thegswami@gmail.com | www.goswami.in

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended)

TO THE BOARD OF DIRECTORS OF MEDICO INTERCONTINENTAL LIMITED

We have reviewed the accompanying Statements of Standalone Unaudited Financial Results of MEDICO INTERCONTINENTAL LIMITED ("the company"), for the quarter ended September 30, 2023 ("the Statement") and year to date from April 01, 2023 to September 30, 2023 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, V. GOSWAMI & CO,
Chartered Accountants
(FRN: 0128769W)

Nilesh Purohit
(Partner)

Mem. No: 162541

Date: - 08/11/2023

Place:-Ahmedabad

UDIN: 23162541BGYOLO2248



MEDICO INTERCONTINENTAL LIMITED																																																						
CIN NO: L24100G1984PLC111413																																																						
Regd. Off: 1-5TH FLOOR, ADIT RAJ ARCADE NR KARMA SHRESHTHA TOWER, 100 FT RD, SATELLITE, Ahmedabad GJ 380015 IN																																																						
Tel No. 079-26742739			E-mail: mail@medicointercontinental.com		Website: www.medicointercontinental.com																																																	
Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended September 30, 2023																																																						
(Rs in Lakhs)																																																						
Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended																																															
		3 Months ended	Preceding 3 Months ended	Corresponding 3 months ended in previous year on	Year to date figure for current period ended	Year to date figure for previous period ended	Previous Year ended																																															
		30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31.03.2023																																															
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited																																															
	Revenues																																																					
1	Revenue from Operations	1712.30	2427.94	1625.51	4140.24	2914.49	7622.55																																															
2	Other Income	8.25	8.36	0.04	16.61	4.02	51.20																																															
3	Total Revenue (A)	1720.55	2436.30	1625.55	4156.85	2918.52	7673.75																																															
	Expenses																																																					
4	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00																																															
	(b) Purchases of stock-in-trade	1263.94	1875.34	1344.71	3139.28	2288.79	6329.81																																															
	(c) Changes in inventories of finished goods and stock-in-trade	61.88	117.23	-41.69	179.11	17.38	-99.56																																															
	(d) Employee benefits expense	94.03	72.64	71.11	166.67	129.38	322.43																																															
	(e) Finance costs	9.46	11.28	19.56	20.74	39.99	61.86																																															
	(f) Depreciation and amortisation expense	6.91	6.68	4.76	13.59	9.26	20.34																																															
	(g) Other expenses	160.91	214.75	109.55	375.66	200.64	544.49																																															
	Total Expenses (B)	1597.14	2297.92	1508.00	3895.06	2685.44	7179.38																																															
5	Profit/(Loss) before exceptional items & tax (1-4)	123.41	138.38	117.55	261.79	233.08	494.37																																															
6	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00																																															
7	Profit/(Loss) for the period from operations before tax (5+6)	123.41	138.38	117.55	261.79	233.08	494.37																																															
8	Tax expense	36.35	36.12	31.18	72.47	60.57	133.55																																															
	(a) Current Tax	37.05	36.76	31.36	73.81	60.89	136.54																																															
	(b) Deferred Tax	-0.70	-0.64	-0.18	-1.34	-0.32	-2.98																																															
9	Profit/(Loss) for the period from continuing operations (7-8)	87.06	102.26	86.37	189.32	172.50	360.82																																															
10	Profit/(loss) for the period from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00																																															
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00																																															
12	Profit/(loss) for the period from Discontinued operations (after tax)	0.00	0.00	0.00	0.00	0.00	0.00																																															
13	Profit/ (loss) for the period (After tax)	87.06	102.26	86.37	189.32	172.50	360.82																																															
14	Other Comprehensive Income		0.00																																																			
15	Total Comprehensive Income for the period (13+14)	87.06	102.26	86.37	189.32	172.50	360.82																																															
	Paid-up Equity Share Capital (Face Value INR 10 each)	1000.000	1000.000	324.900	1000.000	324.900	1000.00																																															
16	Earnings Per Equity Share of Rs. 10 each (for Continuing Operations)																																																					
	(a) Basic - INR	0.87	1.02	2.66	1.89	5.31	5.61																																															
	(b) Diluted - INR	0.87	1.02	2.66	1.89	5.31	5.61																																															
17	Earnings Per Equity Share of Rs. 10 each (for Discontinuing Operations)																																																					
	(a) Basic - INR	0.000	0.000	0.000	0.000	0.000	0.00																																															
	(b) Diluted - INR	0.000	0.000	0.000	0.000	0.000	0.00																																															
18	Earnings Per Equity Share of Rs. 10 each (for Continuing & Discontinuing Operations)																																																					
	(a) Basic - INR	0.87	1.02	2.66	1.89	5.31	5.61																																															
	(b) Diluted - INR	0.87	1.02	2.66	1.89	5.31	5.61																																															
<p>1 The above unaudited Consolidated financial results of the Company for the quarter and half year ended September 30, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 8, 2023. The above results reviewed by statutory auditors and who have expressed an unmodified opinion on these results.</p> <p>2 These results have been prepared in accordance with the Ind AS notified under the Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.</p> <p>3 During the quarter ended September 30, 2023, the company is operating in single segment. So segment reporting is not applicable for this quarter, but segment information shall provides as and when the same shall be operative.</p> <p>4 The Company has continued with old Income Tax rates for the current quarter and is evaluating option available under section 115 BAA of the Income Tax Act, 1961 as per the Taxation Laws (Amendment) Ordinance, 2019.</p> <p>5 The key standalone financial information of the Company is given below:</p> <table border="1"> <thead> <tr> <th rowspan="3">Particulars</th> <th colspan="3">Quarter ended</th> <th colspan="2">Half year ended</th> <th>Year ended</th> </tr> <tr> <th>30-09-2023</th> <th>30-06-2023</th> <th>30-09-2022</th> <th>30-09-2023</th> <th>30-09-2022</th> <th>31-03-2023</th> </tr> <tr> <th>Unaudited</th> <th>Unaudited</th> <th>Unaudited</th> <th>Unaudited</th> <th>Unaudited</th> <th>Audited</th> </tr> </thead> <tbody> <tr> <td>Revenue from operations</td> <td>1004.84</td> <td>1695.77</td> <td>813.47</td> <td>2700.62</td> <td>1433.12</td> <td>4922.50</td> </tr> <tr> <td>Profit before tax</td> <td>65.58</td> <td>65.89</td> <td>50.04</td> <td>131.48</td> <td>100.10</td> <td>237.91</td> </tr> <tr> <td>Net profit after tax</td> <td>47.63</td> <td>48.00</td> <td>37.18</td> <td>95.63</td> <td>74.31</td> <td>170.49</td> </tr> <tr> <td>Total comprehensive income</td> <td>47.63</td> <td>48.00</td> <td>37.18</td> <td>95.63</td> <td>74.31</td> <td>170.49</td> </tr> </tbody> </table> <p>6 The previous period figures have been re-grouped / reclassified, wherever considered necessary.</p>								Particulars	Quarter ended			Half year ended		Year ended	30-09-2023	30-06-2023	30-09-2022	30-09-2023	30-09-2022	31-03-2023	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Revenue from operations	1004.84	1695.77	813.47	2700.62	1433.12	4922.50	Profit before tax	65.58	65.89	50.04	131.48	100.10	237.91	Net profit after tax	47.63	48.00	37.18	95.63	74.31	170.49	Total comprehensive income	47.63	48.00	37.18	95.63	74.31	170.49
Particulars	Quarter ended			Half year ended		Year ended																																																
	30-09-2023	30-06-2023	30-09-2022	30-09-2023	30-09-2022	31-03-2023																																																
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited																																																
Revenue from operations	1004.84	1695.77	813.47	2700.62	1433.12	4922.50																																																
Profit before tax	65.58	65.89	50.04	131.48	100.10	237.91																																																
Net profit after tax	47.63	48.00	37.18	95.63	74.31	170.49																																																
Total comprehensive income	47.63	48.00	37.18	95.63	74.31	170.49																																																

For, Medico Intercontinental Limited

SAMIR SHAH
MANAGING DIRECTOR
DIN: 03350268

Place:- Ahmedabad
Date:- 08/11/2023



MEDICO INTERCONTINENTAL LIMITED

CIN: L24100GJ1984PLC111413

Regd. Off: 1-5TH FLOOR, ADIT RAJ ARCADE NR KARMA SHRESHTHA TOWER, 100 FT RD, SATELLITE, Ahmedabad GJ 380015 IN

Tel No. 079-26742739 E-mail:- mail@medicointercontinental.com Website: www.medicointercontinental.com

Unaudited Consolidated Statement of Assets and Liabilities as at September 30, 2023

(Rs in Lakhs)

	Particulars	As at 30.09.2023	As at 31.03.2023
		Unaudited	Audited
A. ASSETS			
1 Non-current assets			
Property, Plant and Equipment		133.95	144.00
Intangible Assets		113.26	113.36
Financial Assets		-	-
(i) Investments		2.00	2.00
(i) Loans		-	-
(iii) Other financial assets		-	-
Deffered tax assets (Net)		3.46	2.12
Other non-current Assets		1,278.52	656.16
Total Non-Current Assets		1,531.20	917.64
2 Current assets			
Inventories		708.62	887.73
Financial Assets			
(i) Trade Receivables		2,770.93	3,285.03
(ii) Cash and Cash Equivalents		472.65	678.54
(iii) Loans		86.48	-
Other Current Assets		126.76	119.01
Total Current Assets		4,165.44	4,970.31
TOTAL ASSETS		5,696.64	5,887.96
B. EQUITY AND LIABILITIES			
1 Equity			
Equity Share capital		1,000.00	1,000.00
Other Equity		3,297.83	3,118.50
Share Application Money Pending Alloment		-	-
Total Equity		4,297.83	4,118.50
Liabilities			
2 Non-Current Liabilities			
Financial Liabilities			
(i) Borrowings		323.41	221.62
(ii) Lease liability		-	-
(iii) Other financial liabilities		-	-
Long term provisions		13.14	11.12
Deferred tax liabilities (Net)		-	-
Other non-current liabilities		0.30	0.30
Total Non-current liabilities		336.85	233.04
3 Current liabilities			
Financial Liabilities			
(i) Borrowings		-	-
(iii) Trade Payables		259.33	250.30
Due to micor enterprises and small enterprises		-	-
Due to others		187.91	304.29
(iv) Other financial liabilities		507.32	834.63
Other current liabilities		-	-
Short term provisions		77.47	83.41
Current tax liabilities(net)		-	0.04
Current tax liabilities(net)		29.94	63.73
Total Current liabilities		1,061.97	1,536.41
TOTAL EQUITY AND LIABILITIES		5,696.64	5,887.96

For and on behalf of Board of Directors of
MEDICO INTERCONTINENTAL LIMITED

Place:-Ahmedabad
Date:-08/11/2023

SAMIR SHAH
MANAGING DIRECTOR
DIN:- 03350268



MEDICO INTERCONTINENTAL LIMITED

CIN: L24100GJ1984PLC111413

Regd. Off: 1-5TH FLOOR, ADIT RAJ ARCADE NR KARMA SHRESHTHA TOWER, 100 FT RD, SATELLITE, Ahmedabad GJ 380015 IN

Tel No. 079-26742739

E-mail: mail@medicointercontinental.com

Website: www.medicointercontinental.com

Unaudited Consolidated Cash Flow Statement for the half year ended 30 September, 2023

(Rs in Lakhs)			
	PARTICULARS	Half year ended 30.09.2023 (Unaudited)	Half year ended 30.09.2022 (Unaudited)
A.	CASH FLOW FROM OPERATING ACTIVITIES :		
a)	Net Profit/ (Loss) before tax	261.79	233.08
b)	OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	261.79	233.08
	<u>Adjustments For:</u>		
	Depreciation	13.59	9.26
	Finance cost	20.74	39.99
	Dividend received	-0.16	-0.12
	Interest received	-6.25	-0.17
	CASH GENERATED FROM OPERATIONS	289.72	282.03
	<u>Adjustments for</u>		
	Decrease/(Increase) in Inventories	179.11	17.38
	Decrease/(Increase) in Trade Receivables	514.10	-272.17
	Decrease/(Increase) in Short Term Loan and Advances	-86.48	0.00
	Decrease/(Increase) in Other Current Assets/Non Current Assets	-630.11	18.28
	Increase/(Decrease) in Provisions and Other Current Liabilities	-3.98	-32.82
	Increase/(Decrease) in Trade Payables	-443.69	95.62
	Increase/(Decrease) Current Financial Liabilities	0.00	-10.20
	CASH GENERATION FROM OPERATING ACTIVITY	-181.33	98.12
	Income tax Paid Net	(107.60)	-88.07
	NET CASH FROM/(USED IN) OPERATING ACTIVITIES	-288.93	10.05
B.	CASH FLOW FROM INVESTING ACTIVITIES:		
	Purchase of Fixed and Intangible assets	-3.45	-2.32
	Purchase/Sale Investments	0.00	-1.00
	Payment for Intangible Assets	0.00	0.00
	Deposits (net)	-	0.00
	Interest Income	6.25	0.17
	Dividend Income	0.16	0.12
	NET CASH FROM/(USED IN) INVESTING ACTIVITIES	2.96	-3.03
C.	CASH FLOW FROM FINANCING ACTIVITIES:		
	Proceeds from issue of Shares	-	1054.50
	Increase/(Decrease) in Loan and Advances	0.00	0.00
	Proceed from /(Repayment) of Long Term Borrowing net	101.79	3.31
	Proceed from /(Repayment) of Short Term Borrowing net	9.03	10.26
	Dividend Paid	-10.00	0.00
	Finance Costs paid	-20.74	-39.99
	NET CASH FROM/(USED IN) FINANCING ACTIVITIES	80.08	1028.09
	NET INCREASE IN CASH AND CASH EQUIVALENTS	-205.89	1035.11
	CASH AND CASH EQUIVALENTS (At the beginning of the year)	678.54	186.51
	CASH AND CASH EQUIVALENTS (At the end of the year)	472.65	1221.62

For and on behalf of Board of Directors of
MEDICO INTERCONTINENTAL LIMITED

Place: Ahmedabad
Date: -08/11/2023

SAMIR SHAH
MANAGING DIRECTOR
DIN: 03350268





V.GOSWAMI & CO.
CHARTERED ACCOUNTANTS

ICAI REG NO. :- 128769W
RBI UCN NO. :- 897783
C&AG REG NO. :- WR4659
GST :- 24AAFHV3075F1Z7

3, SF, Manek Appt, Nr. Jain Derasar, B/s. Tagor Park, Nehrunagar Circle, Ahmedabad - 380015.
M : +91 94287 33430, +91 97247 28711 | E-mail : thegoswami@gmail.com | www.goswami.in

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

TO THE BOARD OF DIRECTORS OF MEDICO INTERCONTINENTAL LIMITED

We have reviewed the accompanying Statements of Consolidated Unaudited Financial Results of MEDICO INTERCONTINENTAL LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended September 30, 2023 ("the Statement") and year to date from April 01, 2023 to September 30, 2023 attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Parent Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement included the results of following subsidiary company:-

1. EVAGRACE PHARMA PRIVATE LIMITED
2. RITZ FORMULATIONS PRIVATE LIMITED
3. SUNGRACE PHARMA PRIVATE LIMITED
4. AZILLIAN HEALTHCARE PRIVATE LIMITED

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.





V.GOSWAMI & CO.
CHARTERED ACCOUNTANTS

ICAI REG NO. :- 128769W
RBI UCN NO. :- 897783
C&AG REG NO. :- WR4659
GST :- 24AAFHV3075F1Z7

3, SF, Manek Appt, Nr. Jain Derasar, B/s. Tagor Park, Nehrunagar Circle, Ahmedabad - 380015.
M : +91 94287 33430, +91 97247 28711 | E-mail : thegoswami@gmail.com | www.goswami.in

We did not review the interim financial results of the subsidiaries included in the consolidated unaudited financial results, whose financial results and other unaudited financial information reflects total assets of Rs. 1957.79 Lakhs as at September 30, 2023, total revenues of Rs. 900.78 Lakhs and Rs. 1728.81 Lakhs and total net profit Rs. 54.83 Lakhs and Rs109.10 Lakhs for quarter ended September 30, 2023 and for the period from April 01, 2023 to September 30, 2023, respectively, net cash outflow of Rs. 75.62 Lakhs for the period from April 01, 2023 to September 30, 2023, respectively as considered in the Statement whose financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of these matters.

For, V. GOSWAMI & CO,
Chartered Accountants
(FRN: 0128769W)

Nilesh Purohit
(Partner)

Mem. No.: 162541

Date:-08/11/2023

Place: - Ahmedabad

UDIN: 23162541BGYOLP1450



MEDICO INTERCONTINENTAL LIMITED

CIN NO: L24100GJ1984PLC111413

Regd. Off: 1-5th FLOOR, ADIT RAJ ARCADE NR KARMA, SHRESHTHA TOWER, 100 FT RD, SATELLITE, AHMEDABAD - 380015, GUJARAT IN
Tel No. 079-26742739 E-mail:- mail@medicointercontinental.com Website: www.medicointercontinental.com

Statement of Standalone Unaudited Financial Results for the Quarter and Half year ended September 30, 2023

(Rs. in Lakhs)


Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		3 Months ended	Preceding 3 Months ended	Corresponding 3 months ended in previous year on	Year to date figure for current period ended	Year to date figure for previous period ended	Previous Year ended
		30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31.03.2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Revenues						
1	Revenue from Operations	981.19	1690.10	813.44	2671.29	1430.17	4888.18
2	Other Income	23.65	5.68	0.03	29.32	2.94	34.32
3	Total Revenue (A)	1004.84	1695.77	813.47	2700.62	1433.12	4922.50
	Expenses						
(a)	Cost of materials consumed	0.00	0.000	0.00	0.00	0.00	0.00
(b)	Purchases of stock-in-trade	867.71	1387.33	738.18	2255.04	1194.49	4333.98
(c)	Changes in inventories of finished goods and stock-in-trade	-56.60	68.11	-44.74	11.51	-10.56	-127.23
(d)	Employee benefits expense	45.05	25.76	25.55	70.81	48.63	119.76
(e)	Finance costs	1.62	5.07	13.70	6.70	28.37	36.77
(f)	Depreciation and amortisation expense	4.50	4.28	1.86	8.79	3.49	8.66
(g)	Other expenses	76.97	139.32	28.87	216.29	68.60	307.65
	Total Expenses (B)	939.26	1629.88	763.43	2569.14	1333.02	4684.59
5	Profit/(Loss) before exceptional items & tax (1-4)	65.58	65.89	50.04	131.48	100.10	237.91
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) for the period from operations before tax (5+6)	65.58	65.89	50.04	131.48	100.10	237.91
8	Tax expense	17.95	17.90	12.87	35.85	25.79	67.42
(a)	Current Tax	18.61	18.50	13.05	37.11	26.10	69.09
(b)	Deferred Tax	-0.66	-0.60	-0.18	-1.26	-0.31	-1.67
9	Profit/(Loss) for the period from continuing operations (7-8)	47.63	48.00	37.18	95.63	74.31	170.49
10	Profit/(loss) for the period from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) for the period from Discontinued operations (after tax)	0.00	0.00	0.00	0.00	0.00	0.00
13	Profit/ (loss) for the period (After tax)	47.63	48.00	37.18	95.63	74.31	170.49
14	Other Comprehensive Income						
	Other comprehensive Income/(Loss)	0.00	0.00	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (13+14)	47.63	48.00	37.18	95.63	74.31	170.49
	Paid-up Equity Share Capital (Face Value INR 10 each)	1000.00	1000.00	324.90	1000.00	324.90	1000.000
16	Earnings Per Equity Share of Rs. 10 each (for continuing Operations)						
(a)	Basic - INR	0.48	0.48	1.14	0.96	2.29	2.65
(b)	Diluted - INR	0.48	0.48	1.14	0.96	2.29	2.65
17	Earnings Per Equity Share of Rs. 10 each (for discontinuing Operations)						
(a)	Basic - INR	0.00	0.00	0.00	0.00	0.00	0.000
(b)	Diluted - INR	0.00	0.00	0.00	0.00	0.00	0.000
18	Earnings Per Equity Share of Rs. 10 each (for continuing & discontinuing Operations)						
(a)	Basic - INR	0.48	0.48	1.14	0.96	2.29	2.65
(b)	Diluted - INR	0.48	0.48	1.14	0.96	2.29	2.65

- The above unaudited standalone financial results of the Company for the quarter and half year ended September 30, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 08, 2023. The above results reviewed by statutory auditors and who have expressed an unmodified opinion on these results.
- These results have been prepared in accordance with the Ind AS notified under the Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
- During the quarter ended September 30, 2023, the company is operating in single segment. So segment reporting is not applicable for this quarter, but segment information shall provides as and when the same shall be operative.
- The Company has continued with old Income Tax rates for the current quarter and is evaluating option available under section 115 BAA of the Income Tax Act, 1961 as per the Taxation Laws (Amendment) Ordinance, 2019.
- The previous period figures have been re-grouped / reclassified, wherever considered necessary.

Place:- Ahmedabad
Date:-08/11/2023

For and on behalf of Board of Directors of
Medico Intercontinental Limited

Samir Shah
SAMIR SHAH
MANAGING DIRECTOR
DIN: 03350268



Samir Shah

MEDICO INTERCONTINENTAL LIMITED

CIN: L24100GJ1984PLC111413

Regd. Off: 1-5th FLOOR, ADIT RAJ ARCADE NR KARMA, SHRESHTHA TOWER, 100 FT RD, SATELLITE, AHMEDABAD - 380015, GUJARAT IN

Tel No. 079-26742739

E-mail:- mail@medicointercontinental.com

Website: www.medicointercontinental.com

Unaudited Standalone Statement of Assets and Liabilities as at 30 September, 2023

(Rs in Lakhs)

	Particulars	As at 30.09.2023	As at 31.03.2023
		Unaudited	Audited
A. ASSETS			
1 Non-current assets			
Property, Plant and Equipments		41.99	47.64
Financial Assets			
(i) Investments		420.19	420.19
Deferred Tax Assets (Net)		6.12	4.85
Other Non-Current Assets		1,159.19	590.00
Total Non-Current Assets		1,627.49	1,062.69
2 Current assets			
Inventories		357.22	368.73
Financial Assets			
(i) Trade receivables		1,719.97	2,492.23
(ii) Cash and Cash Equivalents		364.68	494.95
(iii) Loans		86.48	-
Other Current Assets		33.05	19.00
Total Current Assets		2,561.40	3,374.91
TOTAL ASSETS		4,188.89	4,437.60
B. EQUITY AND LIABILITIES			
1 Equity			
Equity Share Capital		1,000.00	1,000.00
Other Equity		2,515.50	2,429.87
Total Equity		3,515.50	3,429.87
Liabilities			
2 Non-Current Liabilities			
Financial Liabilities			
(i) Borrowings		280.86	193.65
(ii) Lease liability			
(iii) Other financial liabilities			
Long term provisions		5.98	5.07
Deferred tax liabilities (Net)			
Other non-current liabilities			
Total Non-Current Liabilities		286.85	198.72
3 Current Liabilities			
Financial Liabilities			
(i) Borrowings		33.33	33.33
(ii) Trade Payables		-	-
Due to Micro and Small Enterprises		144.31	278.64
Due to others		203.65	469.42
(iii) Other Financial Liabilities		-	-
Other Current Liabilities		2.20	12.15
Current tax liabilities (net)		3.07	15.47
Short term provisions		-	0.01
Total Current Liabilities		386.55	809.02
TOTAL EQUITY AND LIABILITIES		4,188.89	4,437.60

For and on behalf of Board of Directors of
MEDICO INTERCONTINENTAL LIMITED


SAMIIR SHAH
MANAGING DIRECTOR
DIN: 03350268



Place:- Ahmedabad
Date:-08/11/2023

MEDICO INTERCONTINENTAL LIMITED

CIN: L24100GJ1984PLC111413

Regd. Off: 1-5th FLOOR, ADIT RAJ ARCADE NR KARMA, SHRESHTHA TOWER, 100 FT RD, SATELLITE, AHMEDABAD - 380015, GUJARAT IN
Tel No. 079-26742739 E-mail:- mail@medicointercontinental.com Website: www.medicointercontinental.com

Unaudited Standalone Cash Flow Statement for the half year ended 30 September, 2023

		(Rs in Lakhs)	
	PARTICULARS	Half year ended 30.09.2023 (Unaudited)	Half year ended 30.09.2022 (Unaudited)
A.	CASH FLOW FROM OPERATING ACTIVITIES :		
a)	Net Profit/ (Loss) before tax	131.48	100.10
b)	OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	131.48	100.10
	<u>Adjustments For:</u>		
	Depreciation	8.79	3.49
	Finance costs	6.70	28.37
	Interest and Dividend Income	-21.65	-0.14
	CASH GENERATED FROM OPERATIONS	125.31	131.82
	<u>Adjustments for</u>		
	Decrease/(Increase) in Inventories	11.51	-10.56
	Decrease/(Increase) in Trade Receivables	772.26	-66.58
	Decrease/(Increase) in Other Current assets	-14.05	5.16
	Increase/(Decrease) in Provisions	0.00	0.00
	Increase/(Decrease) in Trade Payables	-400.10	10.04
	Increase/(Decrease) in Current Financial Liabilities - Borrowings	0.00	0.00
	Increase/(Decrease) in Other Current Liabilities	-9.96	1.00
	CASH GENERATION FROM OPERATING ACTIVITY	484.98	70.87
	Income Tax Paid Net	(49.52)	-32.06
	NET CASH FROM/(USED IN) OPERATING ACTIVITIES	435.47	38.81
B.	CASH FLOW FROM INVESTING ACTIVITIES:		
	Purchase of Fixed Assets	-3.13	-2.04
	Decrease/(Increase) in Investment	0.00	0.00
	Gratuity Expenses	0.90	0.00
	Interest and Dividend Income	21.65	0.14
	Other Non-Current Assets	-569.19	-15.00
	NET CASH FROM/(USED IN) INVESTING ACTIVITIES	-549.78	-16.90
C.	CASH FLOW FROM FINANCING ACTIVITIES:		
	Proceeds from issue of Shares	-	1054.50
	Increase/(Decrease) in Loans and Advances	-86.48	0.00
	Proceed from /(Repayment) of Borrowings net	87.22	5.28
	Proceed from /(Repayment) of Short Term Borrowings net	0.00	-1.74
	Dividend Paid	-10.00	0.00
	Finance Costs paid	-6.70	-28.37
	NET CASH FROM/(USED IN) FINANCING ACTIVITIES	-15.96	1029.66
	NET INCREASE IN CASH AND CASH EQUIVALENTS	-130.27	1051.57
	CASH AND CASH EQUIVALENTS (At the beginning of the year)	494.95	128.56
	CASH AND CASH EQUIVALENTS (At the end of the year)	364.68	1180.13

For and on behalf of Board of Directors of
MEDICO INTERCONTINENTAL LIMITED

Place:- Ahmedabad
Date:- 08/11/2023

SAMIR SHAH
MANAGING DIRECTOR
DIN: 03350268

